In 2025, Regeneron Pharmaceuticals conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards.The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Waste Generated | 9,403a | 8,650a | 7,360a | |
Total Waste Recovered | N/A | 2,249a | 1,982.6a | |
Total Hazardous Waste Generated | 1,310a | 1,730a | 1,380a | |
Non-Hazardous Waste Disposed | 5,239.8a | 4,982.4a | 4,066.4a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, Regeneron Pharmaceuticals generated a total of 9,403 metric tonnes of waste.a
Of this amount, 13.93% of Regeneron Pharmaceuticals's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment.78.49% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.The remaining 7.58% was either treated using unspecified methods or not clearly categorized.a
Since 2021, Regeneron Pharmaceuticals's total waste generation increased by 38.89%, including a 8.71% rise in 2025, reflecting a persistent upward trend that could be linked to operational growth, inefficient material use, or limited investment in waste prevention systems.a
Over the same period, Regeneron Pharmaceuticals reduced the hazardousness of its waste by 24.55%, with a further 30.34% decline in 2025, suggesting a sustained and meaningful shift toward safer waste profiles and lower environmental impact.a
Overall, Regeneron Pharmaceuticals is generating more waste but has significantly reduced the share of hazardous materials, suggesting a partial decoupling of volume and toxicity that could reflect more responsible inputs or enhanced treatment.a
In 2025, Regeneron Pharmaceuticals reported that 1,310 metric tonnes of its total waste output were classified as hazardous. This represents 13.93% of its overall waste generation.a
The company treated this hazardous waste using a combination of methods.Only 6% of hazardous waste was recovered, meaning the vast majority was treated through disposal methods such as landfilling or incineration. This raises concerns about the environmental and health risks associated with Regeneron Pharmaceuticals’s current hazardous waste practices.a